Innovative Health, Inc. today announced the availability of three new informational web sessions, being held in early May, to help fill the learning gap left by the cancellation of this year’s Heart Rhythm Scientific Sessions. These sessions will educate administrators and clinicians on new and emerging opportunities for cost reductions through the reprocessing of advanced EP devices.
Interpace Biosciences (NASDAQ: IDXG) announced today that its subsidiary, Interpace Diagnostics, has entered into a contract with Avalon Healthcare Solutions (Avalon), a specialty benefit management company with more than 3 million members, focused on laboratory testing. The new contract, whose terms were not disclosed, includes two of the Southeastern U.S.’s largest Blue Cross Blue Shield …
Today, Aktana, the pioneer in intelligent engagement for global life sciences companies, announced it has added experienced executives with significant scientific, product development, operational, and organizational expertise to its management team. The recent additions bolster the company’s ability to provide life sciences teams with a thoughtful blend of artificial intelligence, machine learning, and human intelligence that allow clients …
Biocoat, Inc., a specialty manufacturer of hydrophilic biomaterial coatings for medical devices, announced today that it has added Jayme Nelson as Director of Business Development to expand customer engagement and to build deeper relationships within Minnesota and the Central U.S. regions.
Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”) today provides the following update regarding the impact of the COVID-19 pandemic on Greenbrook’s business and its response to dealing with the pandemic. As of today, there has been a minimal impact to patient treatment numbers and all of the Company’s active TMS Centers are fully …
Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue Shield of Massachusetts with over 3 million members in Massachusetts and across New England. The contract expands Interpace’s ThyGeNEXT® and ThyraMIR® thyroid assays as both covered services and now in-network services for BCBS …
Harnessing the power of science and revolutionary technology, Colorescience® is proud to announce the launch of seven new SPF protection products to join their award-winning Total Protection™ line.
Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the company’s ThyGeNEXT® and ThyraMIR® tests in the Journal of the American Society of Cytopathology. The article, entitled “Clinical performance of multiplatform mutation panel and microRNA risk classifier in indeterminate thyroid nodules”, will be published online in the …
Interpace Biosciences, Inc. (IDXG) announced today that its agreement with LabCorp® (LH) has been extended for an additional two years, through January 2022. Interpace and LabCorp initially entered in to their collaboration in 2016 through which LabCorp became the first national laboratory in the U.S. to offer electronic ordering and result reporting for Interpace’s proprietary …
The dietary supplement industry now has a state-of-the-art solution for ensuring supply chain transparency and reassuring consumers that what’s listed on an ingredient panel is actually in their product. As a developer of patented and trademarked ingredients, Nutrition21 has introduced this solution with the adoption of CertainT, which is designed to protect the intellectual property …
Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement for Interpace Diagnostics’ ThyraMIR® miRNA classifier for evaluating indeterminate thyroid nodules retroactively to January 1, 2020. This determination increases the Medicare reimbursement for ThyraMIR® from approximately $1800 to $3000 reflecting a re-evaluation of the technical …
Onkos Surgical® is pleased to announce the launch of GenVie™ Magnesium Bone Scaffold, a novel biologic technology that further expands Onkos’ reach in complex limb salvage procedures. GenVie is the first 510(k) cleared magnesium-based bone void filler in the orthopaedic marketplace and is available via a private label distribution agreement with Bone Solutions Inc. (OsteoCrete®) …